Literature DB >> 16905199

Complement activation in autoimmune demyelination: dual role in neuroinflammation and neuroprotection.

Horea Rus1, Cornelia Cudrici, Florin Niculescu, Moon L Shin.   

Abstract

Multiple sclerosis and its animal model experimental allergic encephalomyelitis are inflammatory demyelinating diseases of the central nervous system mediated by activated lymphocytes, macrophages/microglia and the complement system. Complement activation and the C5b-9 terminal complex contribute to the pathogenesis of these diseases through its role to promote demyelination. C5b-9 was also shown to protect oligodendrocytes from apoptosis both in vitro and in vivo. Our findings indicate that activation of complement and C5b-9 assembly plays a pro-inflammatory role in the acute phase, but may also be neuroprotective.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16905199     DOI: 10.1016/j.jneuroim.2006.07.009

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  15 in total

Review 1.  Role of HLA class II genes in susceptibility and resistance to multiple sclerosis: studies using HLA transgenic mice.

Authors:  David Luckey; Dikshya Bastakoty; Ashutosh K Mangalam
Journal:  J Autoimmun       Date:  2011-05-31       Impact factor: 7.094

Review 2.  Neuroprotection in stroke by complement inhibition and immunoglobulin therapy.

Authors:  T V Arumugam; T M Woodruff; J D Lathia; P K Selvaraj; M P Mattson; S M Taylor
Journal:  Neuroscience       Date:  2008-07-12       Impact factor: 3.590

3.  Current and future treatment approaches for neuromyelitis optica.

Authors:  Nicolas Collongues; Jérôme de Seze
Journal:  Ther Adv Neurol Disord       Date:  2011-03       Impact factor: 6.570

Review 4.  The complement system as a biomarker of disease activity and response to treatment in multiple sclerosis.

Authors:  Alexandru Tatomir; Anamaria Talpos-Caia; Freidrich Anselmo; Adam M Kruszewski; Dallas Boodhoo; Violeta Rus; Horea Rus
Journal:  Immunol Res       Date:  2017-12       Impact factor: 2.829

Review 5.  Complement in multiple sclerosis: its role in disease and potential as a biomarker.

Authors:  G Ingram; S Hakobyan; N P Robertson; B P Morgan
Journal:  Clin Exp Immunol       Date:  2008-11-24       Impact factor: 4.330

6.  Deficiency in complement C1q improves histological and functional locomotor outcome after spinal cord injury.

Authors:  Manuel D Galvan; Sabina Luchetti; Adrian M Burgos; Hal X Nguyen; Mitra J Hooshmand; Frank P T Hamers; Aileen J Anderson
Journal:  J Neurosci       Date:  2008-12-17       Impact factor: 6.167

7.  Complement C3 and C4 expression in C1q sufficient and deficient mouse models of Alzheimer's disease.

Authors:  Jun Zhou; Maria I Fonseca; Karntipa Pisalyaput; Andrea J Tenner
Journal:  J Neurochem       Date:  2008-07-09       Impact factor: 5.372

8.  RGC-32 regulates reactive astrocytosis and extracellular matrix deposition in experimental autoimmune encephalomyelitis.

Authors:  Alexandru Tatomir; Cosmin A Tegla; Alvaro Martin; Dallas Boodhoo; Vinh Nguyen; Adam J Sugarman; Armugam Mekala; Freidrich Anselmo; Anamaria Talpos-Caia; Cornelia Cudrici; Tudor C Badea; Violeta Rus; Horea Rus
Journal:  Immunol Res       Date:  2018-08       Impact factor: 2.829

Review 9.  Complement activation in the injured central nervous system: another dual-edged sword?

Authors:  Faith H Brennan; Aileen J Anderson; Stephen M Taylor; Trent M Woodruff; Marc J Ruitenberg
Journal:  J Neuroinflammation       Date:  2012-06-21       Impact factor: 8.322

10.  Plaque complement activation and cognitive loss in Alzheimer's disease.

Authors:  David A Loeffler; Dianne M Camp; David A Bennett
Journal:  J Neuroinflammation       Date:  2008-03-11       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.